This session will bring practical, evidence-based insights into radiotherapy decision-making for Stage III NSCLC, including modern staging, handling transitions from neoadjuvant therapy, and risk-adapted post-operative approaches.
Whether you’re a clinician, researcher, or allied professional, this webinar offers valuable perspectives you won’t want to miss.
Patient Insights from TTLC with Communications Committee Member Dusty Joy Donaldson of LiveLung:
After hearing Dr. Carl Gay of MD Anderson, Dusty shared: “Knowing that there are currently limited options for those whose NSCLC has transformed into SCLC is heartbreaking, as this is an issue we see more frequently now. However, hearing that there are more options pre-transformation has created a mission to ensure patients at risk get tested.”
02/21/2026
Patient Insights from TTLC with Communications Committee Member Dusty Joy Donaldson from LiveLung
At TTLC, Jane Perlmutter took the stage and reminded us exactly why this work matters.
Having faced six primary cancer diagnoses, she shared an extraordinary journey shaped by resilience, cutting-edge science, and the life-changing impact of clinical trials.
Her story is not just one of survival; it’s a testament to progress.
Jane is a patient of Dr. Shiresh Gadgeel, MD, co-chair of TTLC, bringing the conference’s scientific leadership and patient impact full circle.
02/20/2026
After an amazing first day at the IASLC 2026 Targeted Therapies of Lung Cancer Conference, we’re kicking off Day 2 with an energized group at the Women in Thoracic Oncology breakfast session.
The room is buzzing this morning. A reminder that content will be available after the conference on our education platform, Lung Cancer 360.
A bustling Day 1 at the IASLC 2026 Targeted Therapies of Lung Cancer Conference. The energy is high, and attendees are looking ahead to an exciting few days of science and collaboration.
Not with us in person? IASLC members receive access to conference content after the event on our educational platform, Lung Cancer 360.
Stay tuned for a special episode of Lung Cancer Considered featuring conference highlights.
02/18/2026
Applications are still open for two incredible STARS opportunities!
💻 STARS Patient Research Advocate (PRA) Program
An all-virtual training program for patients and caregivers who want to engage meaningfully in lung cancer research.
🌍 STARS Scholar Program
An in-person opportunity at WCLC 2026 for experienced research advocates, including travel support and exclusive programming.
🗓 Application deadline: March 12, 2026
Whether you’re just beginning your advocacy journey or ready to take your impact to the global stage, STARS offers a pathway to grow, connect, and contribute.
In this new episode, Dr. Steven Liu leads a virtual tumor board with Dr. Raffaele Califano and Dr. Jessica Menis, focusing on current treatment strategies for extensive-stage small cell lung cancer. They review recent clinical updates and share how these developments are shaping real-world decision-making.
Join us in Dublin for the IASLC 2026 Hot Topic Meeting at Trinity College Dublin! This focused, two-day event will explore the evolving challenge of resistance to immunotherapy in lung cancer care in an interactive and collaborative setting.
What to expect:
• Expert-led presentations
• Panel discussions with practical insights
• Interactive sessions that encourage conversation and shared learning
🗓️ June 26–27
Registration and abstract submissions open in March.
📝 Applications Are Still Open – IASLC Reviewer Workshop at WCLC 2026!
IASLC, in collaboration with Journal of Thoracic Oncology (JTO) and JTO Clinical and Research Reports (JTO CRR), is still accepting applications for the one-day Reviewer Workshop at the IASLC 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea.
This interactive workshop is designed to strengthen manuscript review skills for early- and mid-career investigators through practical guidance from experienced editors and faculty.
📅 September 15, 2026
📍 Seoul, Republic of Korea
Director: Alex A. Adjei, MD, PhD, FACP
Who Should Apply?
✔ IASLC members within 15 years of completing specialist training
✔ Strong command of English
✔ Priority given to current JTO & JTO CRR reviewers
✔ Open to applicants from the Asia-Pacific region
✔ Non-members must apply for IASLC membership
Why Apply?
✨ Complimentary WCLC 2026 registration
✨ Travel & accommodation covered
✨ Expert training in academic publishing & peer review
📄 Application Requirements:
• CV (education & publications)
• Letter of Commitment (max 300 words)
• Letter of Support from supervisor, department head, or IASLC member
🎧 Lung Cancer Considered episode in Cantonese!
Guest host Dr. Molly Li brings together thoracic surgeons Dr. Shuben Li and Dr. Calvin S. H. Ng for a thoughtful conversation on surgical care for early-stage NSCLC.
They discuss:
• Surgical management strategies
• Lobar vs. sublobar resection
• Endobronchial therapy
• Tubeless anesthesia and other innovations
This episode is part of IASLC’s world languages series, expanding access to expert insights across the global community.
Be the first to know and let us send you an email when International Association for the Study of Lung Cancer posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Contact The Practice
Send a message to International Association for the Study of Lung Cancer:
The International Association for the Study of Lung Cancer (IASLC) is on a mission to conquer thoracic cancers worldwide. Through hosting global conferences, funding cutting-edge research and educating the health care community and the general public on all aspects of thoracic cancers, the IASLC strives to alleviate the burden lung cancer places on patients, families and communities.
Each year, the IASLC hosts the World Conference on Lung Cancer (WCLC), the world’s largest meeting dedicated solely to thoracic cancers. The WCLC regularly attracts over 7,000 thoracic cancer specialists from over 100 countries and offers attendees the chance to collaborate and network while learning about the latest updates in the field.
The IASLC Foundation supports the education of research fellows - who are the next generation of lung cancer physicians and scientists - by funding research fellowships. Since its inception, the foundation has given nearly $3.5 million to lung cancer research, and that number is on the rise.
Additionally, the IASLC publishes the Journal of Thoracic Oncology (JTO), a primary source for educational information related to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Over its publication history, the JTO has established itself as an authoritative resource in the field, and the journal recently saw its impact factor increase from 6.595 in 2016 to 10.336 in 2017.
The IASLC is a global and multidisciplinary organization that desires to build a international and inclusive lung cancer community. Whether you are an oncologist or surgeon, advocate or patient, we welcome your expertise, experience and voice in the ongoing fight against lung cancer. Join us!
